The Employees’ State Insurance Corporation (ESIC) on October 14, 2026, has reported Paracetamol Tablets IP 650 mg, Batch No. 159, supplied by M/s Alpa Laboratories Ltd., as “Not of Standard Quality” (NSQ). The Government Analyst, Jalukbari, Guwahati, reported that the sample failed to conform to Indian Pharmacopoeia (IP) standards with respect to the dissolution test for Paracetamol Tablets IP 650 mg. The test report number is SDTL/L/SB/2026/1536, dated September 30, 2026.
ESIC has directed the Medical Store to immediately withdraw the affected batch from substores, dispensaries and patient care areas and discontinue its use. The vendor must be requested to replace the stock with another batch within 15 days or collect the stock and refund the payment. In case of non-compliance, risk purchase action may be initiated, and testing costs, if any, recovered from the vendor. Further action must be taken in accordance with the applicable clauses of the DG-ESIC Tender Enquiry/Rate Contract, and records of the action taken must be maintained by the respective user units.
[File No. U-25/12/NSQ/2023-MedV(E-178406)/324]
